Mira Katan received her MD from the University of Zurich and was trained in Neurology at the University Hospital of Basel (both in Switzerland) before she moved to New York (US) for a research fellowship at Columbia University (New York, US). Currently she is leading the comprehensive Stroke Unit of the University Hospital of Basel. Mira Katan is broadly interested in the diagnosis, management, treatment, and outcome of stroke patients. Her research focuses on the identification and validation of different biomarkers to provide more precise information (i.e. precision medicine approach) for advanced early risk stratification but also improved identification of the underlying stroke etiology for an individually tailored secondary prevention. She has initiated and conducted several prospective large cohort studies (COSMOS, Co-RISK, BIOSIGNAL) and built up a multicenter blood biobank of acute ischemic stroke patients. Moreover, she is the PI of the MOSES trial, the first blood biomarker-guided multicenter, international RCT in secondary stroke prevention in Europe. Her research activities are reflected in the publication of more than 90 peer-reviewed articles as well as by several awards. She is member of the editorial board of several journals (such as NEUROLOGY and STROKE) and serves as secretary general of the Swiss-Stroke-Society.